DaVita (Total Renal Care Holdings, Inc.)
Quarterly financial highlights include:
-- Continental U.S. dialysis revenue per treatment (excluding lab,
pharmacy and other revenue) in the second quarter was $249.23 as
compared to $247.01 in the first quarter, or a 1% increase.
-- Continental U.S. DSO at quarter end was 80 days. This represents a
three-day improvement from the first quarter. Excluding the suspended
Florida laboratory Medicare receivables of $38 million, DSO was 71 days
or a four-day improvement during the quarter.
-- Net cash provided by operations was $49 million in the second quarter,
after the payment of $11 million for the shareholder litigation
settlement. Routine capital asset purchases and growth capital
expenditures were approximately $8 million.
-- Consolidated revenues for the three and six months ended June 30, 2000
were $379 million and $751 million, respectively. Revenues from the
continental U.S. were $344 million and $684 million, respectively.
Revenues from the non-continental operations were $35 million and
$67 million, respectively.
-- Total continental U.S. treatments for the second quarter were
1,335,873. Non-acquired treatment growth was 6.4%, which included same
center treatment growth of 5.0%.
-- Application of the proceeds of the sale of the Company's
non-continental operations and outpatient pharmacy business reduced the
Company's outstanding debt obligations by approximately $128 million.
Net debt (total debt less cash) was reduced by approximately
$174 million, or 13%, from $1.29 billion to $1.12 billion as of the end
of the quarter.
-- In July 2000, DaVita completed a restructuring of its revolving and
term loan credit facilities. The Company is now in compliance with all
credit facility covenants. Accordingly, the Company's credit facility
debt and subordinated notes have been reclassified from current to
long-term, except for the current portion. Interest rates related to
these obligations have returned to the pre-default rates that are based
on LIBOR plus an applicable margin.
-- At June 30, 2000 we operated 489 outpatient centers in the continental
U.S. serving over 40,000 patients. During the quarter, we opened
5 de novo dialysis facilities, added 4 managed units and closed
4 under-performing centers. Included in our continental patient and
facility count are 4,500 patients in 55 centers under management. We
also provide acute hemodialysis services to inpatients at
301 continental U.S. hospitals.
Specifics of the second quarter charges are as follows:
-- $4.4 million non-cash impairment and valuation adjustments primarily
related to the divestiture of our non-continental operations,
-- $10.8 million cash charge related to the settlement of our shareholder
class action lawsuit,
-- $4.7 million non-cash write-off of a cumulative foreign currency
translation loss from our non-continental business, and
-- $2.7 million non-cash charge, included in tax expense, for the
write-off of a deferred tax asset associated with medical director
stock options that have been cancelled.
These previously disclosed charges total $17.7 million on an after tax basis.
As a result of the restructuring of our revolving and term loan credit facilities in July 2000, our third quarter results will include the write-off of certain related financing costs. These write-offs will be reflected principally as an extraordinary loss of $3.5 million, net of tax. Additionally, there will be $1.2 million of pre-tax costs written-off which will be included in debt expense. Other previously disclosed potential future charges and expenses include potential charges related to the unwinding of poor performing contracts, partnerships or investments in dialysis related companies, and any potential losses related to unfavorable resolution of the ongoing payment suspension of Medicare claims for our Florida laboratory.
Kent Thiry, Chairman and CEO observed, "The DaVita team continues to demonstrate great resolve in our quest to meet the expectations of each of our constituencies. Our near-term prospects for sustaining our march to achieving operating excellence are good. However, we still advise caution with respect to long-term industry margins, in particular because, rate reductions in the higher pay segments would be difficult to offset."
This release contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding our financial performance and involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the uncertainties associated with governmental regulation, general economic and other market conditions, and the "risk factors" set forth in the Company's filings with the Securities and Exchange Commission, including but not limited to (1) the risks relating to the large amount and terms of the Company's outstanding debt, (2) possible changes in Medicare, Medicaid and private reimbursement rates, and (3) the high concentration of profits generated from private indemnity patients, which represent a small percentage of our total patients. The forward-looking statements should be considered in light of these risks and uncertainties.
DAVITA
(TOTAL RENAL CARE HOLDINGS, INC.)
CONSOLIDATED BALANCE SHEETS
(in thousands except per share data)
June 30, December 31,
2000 1999
ASSETS
Cash and cash equivalents $190,672 $107,981
Accounts receivable, less
allowance of $62,828,
and $67,315, respectively 303,355 390,329
Inventories 19,865 32,916
Other current assets 21,700 32,082
Income tax receivable 25,856 45,645
Deferred income taxes 44,861 45,795
Total current assets 606,309 654,748
Property and equipment, net 248,033 285,449
Intangible assets, net 957,322 1,069,672
Investments in third-party
dialysis businesses 35,814 35,552
Deferred taxes 5,407 6,553
Other long-term assets 2,264 4,744
$1,855,149 $2,056,718
LIABILITIES AND SHAREHOLDERS' EQUITY
Accounts payable $72,888 $121,561
Accrued compensation and benefits 50,104 47,647
Other liabilities 81,420 77,141
Current portion of long-term debt 121,237 26,585
Long-term debt potentially callable
under covenant provisions -- 1,425,610
Total current liabilities 325,649 1,698,544
Long-term debt, less $0, and $1,425,610
potentially callable classified
as current 1,188,134 5,696
Other long-term liabilities 3,921 3,497
Minority interests 17,395 22,577
Shareholders' equity
Preferred stock ($0.001 par value;
5,000,000 shares authorized;
none issued or outstanding)
Common stock ($0.001 par value,
195,000,000 shares authorized;
81,565,215 and 81,193,011 shares
issued and outstanding) 82 81
Additional paid-in capital. 426,428 426,025
Notes receivable from shareholders. (160) (192)
Accumulated other comprehensive loss -- (4,718)
Accumulated deficit (106,300) (94,792)
Total shareholders' equity 320,050 326,404
$1,855,149 $2,056,718
DAVITA
(TOTAL RENAL CARE HOLDINGS, INC.)
CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share data)
Three months ended June 30, Six months ended June 30,
2000 1999 2000 1999
Net operating
revenues $378,908 $352,819 $751,021 $705,063
Operating expenses
Dialysis and lab
facilities. 267,714 250,548 527,012 480,188
General and
administrative. 31,619 29,559 63,540 53,167
Depreciation and
amortization. 29,670 26,758 57,388 53,148
Provision for
uncollectible
accounts. 12,648 35,707 25,507 46,185
Impairments and
valuation
adjustments 4,414 16,600 4,414 16,600
Total operating
expenses 346,065 359,172 677,861 649,288
Operating income
(loss) 32,843 (6,353) 73,160 55,775
Other income (loss) (11,984) 1,934 (10,589) 3,264
Debt expense 34,482 24,905 67,647 48,208
Minority interests
in income of
consolidated
subsidiaries (1,023) (2,521) (2,021) (4,839)
Income (loss) before
income taxes. (14,646) (31,845) (7,097) 5,992
Income tax expense
(benefit) 709 (9,786) 4,411 4,844
Net income (loss) $(15,355) $(22,059) $(11,508) $ 1,148
Earnings (loss)
per share. $(0.19) $(0.27) $(0.14) $0.01
Earnings (loss)
per share-assuming
dilution $(0.19) $(0.27) $(0.14) $0.01
SUPPLEMENTAL INFORMATION
DAVITA
(TOTAL RENAL CARE HOLDINGS, INC.)
CONTINENTAL U.S. OPERATING INCOME AND EARNINGS BEFORE
INTEREST, TAXES, DEPRECIATION AND AMORTIZATION
THREE MONTHS ENDED JUNE 30, 2000
(in thousands)
Net operating revenues $344,331
Operating expenses
Dialysis and lab facilities 240,385
General and administrative 29,815
Depreciation and amortization 25,700
Provision for uncollectible
accounts. 11,825
Impairments and valuation
adjustments 4,414
Total operating expenses. 312,139
Operating income $32,192
EBITDA pre-impairment $62,306
Owned Centers 434
Treatments 1,335,873
Revenue per treatment
(excludes lab,
management fees
and other revenue) $249.23
SOURCE: Total Renal Care Holdings, Inc.
Contact: LeAnne Zumwalt, Investor Relations of Total Renal Care, Inc.,
310-750-2072
Website: http://www.totalrenal.com/